Onconetix (ONCO) Retained Earnings (2021 - 2026)
Onconetix (ONCO) posted quarterly Retained Earnings of $148.2 million for Q1 2026, up 218.22% year-over-year from $46.6 million in Q1 2025, and little changed quarter-over-quarter from $147.8 million in Q4 2025.
Onconetix (ONCO) Retained Earnings (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Retained Earnings for 6 consecutive years, with $148.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 218.22% year-over-year to $148.2 million; the TTM figure through Mar 2026 stood at $148.2 million (up 218.22% YoY), while the FY2025 annual figure was $147.8 million, up 227.79% from the prior year.
- Retained Earnings held at $148.2 million in Q1 2026 per ONCO's latest filing, from $147.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at $148.2 million in Q1 2026 and bottomed at -$136.9 million in Q3 2025.
- Historically, Retained Earnings has averaged -$3.6 million across 5 years, with a median of -$8.0 million in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings soared 810.65% — and 2024, when it tumbled 334.04%.
- Onconetix's Retained Earnings stood at $42.3 million in 2022, then advanced by 16.77% to $49.4 million in 2023, then slumped by 334.04% to -$115.7 million in 2024, then surged by 227.79% to $147.8 million in 2025, then climbed by 0.28% to $148.2 million in 2026.
- Business Quant data shows ONCO's Retained Earnings at $148.2 million in Q1 2026, $147.8 million in Q4 2025, and -$136.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 152.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 152.96 Mn |
| Mar 31, 2026 | 148.24 Mn |
| Dec 31, 2025 | 147.84 Mn |
| Sep 30, 2025 | -136.90 Mn |
| Jun 30, 2025 | -128.10 Mn |
| Mar 31, 2025 | -125.40 Mn |
| Dec 31, 2024 | -115.68 Mn |
| Sep 30, 2024 | 119.56 Mn |
| Jun 30, 2024 | -82.21 Mn |
| Mar 31, 2024 | -67.90 Mn |
| Dec 31, 2023 | 49.43 Mn |
| Sep 30, 2023 | 45.30 Mn |
| Jun 30, 2023 | 42.79 Mn |
| Mar 31, 2023 | -22.22 Mn |
| Dec 31, 2022 | 42.33 Mn |
| Sep 30, 2022 | 41.89 Mn |
| Jun 30, 2022 | -12.29 Mn |
| Mar 31, 2022 | -8.03 Mn |
| Dec 31, 2021 | -5.96 Mn |